Literature DB >> 18214651

Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration.

Isabella Quinti1, Annarosa Soresina, Carlo Agostini, Giuseppe Spadaro, Andrea Matucci, Ifigeneia Sfika, Helene Martini, Federica Borghese, Andrea Guerra, Vultaggio Alessandra, Marcella Visentini, Alessandro Plebani, Massimo Fiorilli.   

Abstract

INTRODUCTION: The multicenter prospective study provides information on adverse reactions to intravenous and subcutaneous immunoglobulin treatment in a cohort of 262 patients with common variable immunodeficiency. Severe adverse reactions are a rare but unpredictable event that might occur also in patients who tolerate substitutive intravenous or subcutaneous immunoglobulin therapy for months or years.
RESULTS: Subcutaneous therapy has been proved to be a safe option in the 13 patients who had to stop intravenous treatment and who remained out of immunoglobulin replacement for long periods of time. However, severe reactions to subcutaneous therapy occurred at the first or after several subcutaneous immunoglobulin administrations in 2 out of 13 patients.
CONCLUSION: Therefore, patients with previous severe reactions to intravenous immunoglobulin should be considered at particularly high risk for reaction to subcutaneous administration. In these cases, switching from in-hospital administration to home self-administration should be done with extreme care.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18214651     DOI: 10.1007/s10875-007-9169-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  18 in total

Review 1.  The use of intravenous immune globulin in immunodeficiency diseases.

Authors:  R H Buckley; R I Schiff
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

2.  Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.

Authors:  R I Schiff; L W Williams; R P Nelson; R H Buckley; W Burks; R A Good
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

3.  Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.

Authors:  Haig Tcheurekdjian; Jamila Martin; Roger Kobayashi; Richard Wasserman; Robert Hostoffer
Journal:  Allergy Asthma Proc       Date:  2006 Nov-Dec       Impact factor: 2.587

4.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 5.  Adverse events associated with intravenous immunoglobulin therapy.

Authors:  David J Hamrock
Journal:  Int Immunopharmacol       Date:  2005-12-13       Impact factor: 4.932

6.  Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

Authors:  Ann Gardulf; Uwe Nicolay; Dipl Math; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz T Costa-Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Nuria Matamoros; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Allergy Clin Immunol       Date:  2004-10       Impact factor: 10.793

7.  Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy.

Authors:  U Sundin; S Nava; L Hammarström
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

Review 8.  Adverse effects of intravenous immunoglobulin.

Authors:  S A Misbah; H M Chapel
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

9.  European surveillance of immunoglobulin safety--results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries.

Authors:  Isabella Quinti; Marina Pierdominici; Marco Marziali; Antonello Giovannetti; Simona Donnanno; Helen Chapel; Janne Bjorkander; Fernando Aiuti
Journal:  Clin Immunol       Date:  2002-09       Impact factor: 3.969

10.  Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency.

Authors:  Isabella Quinti; Annarosa Soresina; Giuseppe Spadaro; Silvana Martino; Simona Donnanno; Carlo Agostini; Pignata Claudio; Dammacco Franco; Anna Maria Pesce; Federica Borghese; Andrea Guerra; Roberto Rondelli; Alessandro Plebani
Journal:  J Clin Immunol       Date:  2007-02-14       Impact factor: 8.542

View more
  14 in total

1.  Intravenous immunoglobulin replacement treatment reduces in vivo elastase secretion in patients with common variable immune disorders.

Authors:  Alessandro Prezzo; Filomena M Cavaliere; Cinzia Milito; Caterina Bilotta; Metello Iacobini; Isabella Quinti
Journal:  Blood Transfus       Date:  2018-07-17       Impact factor: 3.443

Review 2.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

3.  Management of a pregnant woman with common variable immunodeficiency and previous reactions to intravenous IgG administration.

Authors:  Maria Giovanna Danieli; Romina Moretti; Lucia Pettinari; Simona Gambini
Journal:  BMJ Case Rep       Date:  2012-12-17

4.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

Review 5.  Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency.

Authors:  C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

Review 6.  Immunoglobulin replacement therapy in children.

Authors:  Maria Garcia-Lloret; Sean McGhee; Talal A Chatila
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

7.  Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-11-01

Review 8.  Primary immunodeficiencies of the B lymphocyte.

Authors:  Ana Moise; Filofteia Daniela Nedelcu; Maria Adela Toader; Steluta Mihaela Sora; Anca Tica; Denisa Elena Ferastraoaru; Ileana Constantinescu
Journal:  J Med Life       Date:  2010 Jan-Mar

9.  Proteomic analysis of sera from common variable immunodeficiency patients undergoing replacement intravenous immunoglobulin therapy.

Authors:  Giuseppe Spadaro; Concetta D'Orio; Arturo Genovese; Antonella Galeotafiore; Chiara D'Ambrosio; Stefano Di Giovanni; Monica Vitale; Mario Capasso; Vincenzo Lamberti; Andrea Scaloni; Gianni Marone; Nicola Zambrano
Journal:  J Biomed Biotechnol       Date:  2011-09-22

10.  High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis.

Authors:  Cherin Patrick; Delain Jean-Christophe; Crave Jean-Charles; Cartry Odile
Journal:  Case Rep Rheumatol       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.